Steven Sterious, MD
Urology · Philadelphia, PANPI 1437318011
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $58,343 of the $71,583 with a category attached, or 81.5%. Procept Biorobotics Corporation accounts for 97.7% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $31,083 and has fallen 99.0% since, to $316 in 2025. Among urology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $447.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$70K
- Coloplast$303
- Dentsply IH AB$287
- Astellas Pharma US Inc$166
- Sumitomo Pharma America, Inc.$129
- Ambu Inc.$117
- plus $641 from 17 others
What the payments were for
- Consulting fees$58,34382%
- Travel & lodging$9,85414%
- Food & beverage$3,3865%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 100 | $69,940 |
| Coloplast | 11 | $303 |
| Dentsply IH AB | 10 | $287 |
| Astellas Pharma US Inc | 4 | $166 |
| Sumitomo Pharma America, Inc. | 5 | $129 |
| Ambu Inc. | 3 | $117 |
| Laborie Medical Technologies Corp. | 1 | $87 |
| 180 Medical, Inc. | 2 | $85 |
| Civco Medical Instruments | 1 | $51 |
| Alnylam Pharmaceuticals Inc. | 3 | $49 |
| Boston Scientific | 3 | $48 |
| Johnson & Johnson(2 entities) | 2 | $42 |
| Convatec Inc. | 2 | $38 |
| Endo Pharmaceuticals Inc. | 2 | $35 |
| Ferring Pharmaceuticals Inc. | 2 | $31 |
| Olympus America Inc. | 1 | $29 |
| AbbVie | 2 | $27 |
| Teleflex LLC | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $22 |
| Acerus Pharmaceuticals Corporation | 1 | $20 |
| Progenics Pharmaceuticals, Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$67,666
How this compares
$71,583 in reported general payments places this provider in the 95th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 34 | $32,245 |
| Solifenacin Succinate | 193 | $5,941 |
| Tamsulosin Hcl | 371 | $4,669 |
| Finasteride | 151 | $3,284 |
| Oxybutynin Chloride ErOxybutynin Chloride | 145 | $3,109 |
| Tolterodine Tartrate ErTolterodine Tartrate | 24 | $1,956 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 72 | $942 |
| Testosterone Cypionate | 26 | $773 |
| Silodosin | 17 | $603 |
| Ciprofloxacin Hcl | 34 | $390 |
| Sildenafil Citrate | 21 | $350 |
| Cephalexin | 60 | $161 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $104 |
| Tadalafil | 15 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $166 | $32,24534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 596 urology providers in Pennsylvania.
Other urology in Philadelphia
- Demetrius BagleyPhiladelphia$739K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
- Siobhan HartiganPhiladelphia$121K
- Paul ChungPhiladelphia$120K
- William JaffePhiladelphia$119K
- Robert UzzoPhiladelphia$111K
- Jay SimhanPhiladelphia$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.